Abstract
Purpose :
The nuclear factor kappa (NFκ) B transcription pathway is the central regulator of ocular surface inflammation and disease. We have reported that the probiotic bacteria metabolite (JE) produced by Lactobacillus fermentum suppresses production of the inflammatory cytokine (IL-6) by human corneal epithelial cells (HCECs). The purpose of this study is to determine whether probiotic bacterial metabolite inhibits NFκB activation mediated by Toll-like Receptor 5 agonist on human corneal epithelial cells.
Methods :
SV40-immortalized human corneal epithelial cells were cultured in DMEM/F12 medium. HCECs were pretreated with a probiotic bacteria-derived metabolite (JE) produced by Lactobacillus fermentum and subsequently exposed to TLR5 agonist (flagellin from Pseudomonas aeruginosa). NFκB activation of cell lysis were measured using NFκB p65 (pS536) Simplestep ELISA Kit. The inflammatory cytokine IL-6 within the culture supernatants was evaluated by ELISA.
Results :
Exposure of HCECs to TLR5 agonist flagellin from Pseudomonas aeruginosa resulted in activation of NFκB; The probiotic bacteria-derived metabolite (JE) inhibited flagellin-induced NFκB activation. HCECs produced large amounts of inflammation cytokine IL-6 in response to TLR5 agonist flagellin from Pseudomonas aeruginosa. Probiotic bacteria-derived metabolite (JE) produced by Lactobacillus fermentum suppressed the TLR5 agonist-induced IL-6 production.
Conclusions :
Probiotic bacterial metabolite (JE) can suppress NFκB activation leading to reduced production of Inflammation Cytokine IL-6 to TLR5 agonist flagellin from Pseudomonas aeruginosa. This data suggests that JE has a potential to be used as an anti-ocular inflammatory agent.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.